Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
复制标题
DOI：
10.1089/aid.2020.0197
复制
发表时间：
2021-01-12
影响因子：
1.5
通讯作者：
Rubin, Leah H.
中科院分区：
文献类型：
--
作者：
Lahiri, Cecile D.;Xu, Yanxun;Rubin, Leah H.
在改用整合酶抑制剂（INSTI）和/或替诺福韦艾拉酚胺（TAF）后，对女性的体重和体重指数（BMI）变化进行了评估。从 2006 年到 2019 年，共有 1,458 名艾滋病毒感染者参加了妇女机构间艾滋病毒研究并接受抗逆转录病毒治疗 (ART)，并且在改用 INSTI 和/或 TAF 之前和之后进行了 >= 1 次研究访视。使用多变量线性混合效应模型比较转用 INSTI（按类别和类型）和/或 TAF 前后的体重和 BMI；所有模型还根据转换前是否存在肥胖进行分层（BMI >= 30 vs BMI >= 30）。
Weight and body mass index (BMI) change was assessed among women after switch to integrase inhibitors (INSTIs) and/or tenofovir alafenamide (TAF). From 2006 to 2019, 1,458 women living with HIV enrolled in the Women's Interagency HIV Study and on antiretroviral therapy (ART) with >= 1 study visit before and after switching to INSTIs and/or TAF were included. Weight and BMI were compared pre- and postswitch to INSTI (by class and type) and/or TAF using multivariable linear mixed effects models; all models were also stratified by preswitch presence or absence of obesity (BMI >= 30 vs.